A landmark mouse study (Stanger, Tanaka and Melton, 2007) showed that final pancreas size is fixed by the number of embryonic progenitors: temporally controlled ablation of Pdx1+ pancreatic progenitors produces a permanently small pancreas with no compensatory regrowth, titrating progenitor input by blastocyst complementation varies final pancreas size, whereas the liver restores normal mass after equivalent embryonic progenitor loss. The mechanistic questions this raised remain open after two decades. First, it is still unknown whether pancreatic progenitor proliferative output is limited cell-autonomously — for example by an intrinsic division-counting or proliferative set-point program — or by non-epithelial niche components such as the pancreatic mesenchyme, whose paracrine signal IGF2 demonstrably scales pancreatic growth. Second, the molecular pathways that would impose the limit (FGF, Notch, Wnt/β-catenin, Hippo/YAP–Tead, miRNA and cell-cycle regulators) are known only as individual modulators: none accounts for the size limit, and activating growth pathways can even shrink the organ. Third, the progenitor-number-limited versus regulative dichotomy has been empirically extended to kidney, lung, thymus and adipose tissue, but no principle predicts which organs use which mode or how the mode relates to regenerative capacity, and interspecies chimeras show that host-level cues can override donor-intrinsic size programs. The problem — identify the mechanism that limits pancreas size by embryonic progenitor number, and the rule governing which organs are progenitor-number-limited — remains open.

Background

How a developing animal sets the final size of each of its organs is a long-standing open problem in developmental biology. For some tissues — blood and the central nervous system are classic examples — organ mass is largely determined by extrinsic, growth-factor-regulated cell proliferation and cell death, so that cell loss can be compensated and the tissue reaches a target size set by the body's demands. Liver growth is regulative in this sense: after surgical removal or embryonic progenitor loss, the liver restores lost mass and adjusts its size to that of the organism. Whether all organs obey such extrinsic, regulative control, or whether some carry intrinsic developmental limits, was unresolved.

The pancreas develops from buds of the posterior foregut endoderm. Around embryonic day 8.5–9.5 in the mouse, cells expressing the transcription factor Pdx1 (pancreatic and duodenal homeobox 1) form a multipotent progenitor epithelium; these multipotent progenitor cells give rise to all three pancreatic lineages — hormone-secreting endocrine cells, enzyme-secreting acinar cells, and ducts. The epithelium is surrounded by mesenchyme, non-epithelial connective tissue that supplies paracrine signals (including fibroblast growth factor 10, FGF10, and later insulin-like growth factor 2, IGF2, an imprinted growth-factor gene) required for progenitor proliferation. Whether size information resides in the epithelial progenitors themselves or in the mesenchyme is precisely one of the unresolved issues.

Stanger, Tanaka and Melton (2007) addressed this with two designs. First, using a tetracycline-controlled system in which the Pdx1 promoter drives a tetracycline transactivator that turns on diphtheria toxin A chain (DTA), they ablated pancreatic progenitors at defined embryonic stages: early ablation permanently reduced pancreas mass with essentially no compensatory regrowth, through adulthood. Second, by blastocyst complementation — injecting embryonic stem cells into Pdx1-deficient (pancreas-forming-disabled) blastocysts so that only the injected cells can build a pancreas — they varied the number of contributing progenitors and found that final pancreas size varies with progenitor input. In sharp contrast, ablating early liver progenitors (hepatoblasts, via a liver-specific driver) allowed the liver to recover normal weight within days. The paper concluded that final pancreas size is constrained by an intrinsic program established early in development — the size of the progenitor pool set aside in the pancreatic bud — essentially not subject to growth compensation, whereas liver size is regulative.

Several mechanistic threads have since been built on this foundation. The Hippo pathway — a kinase cascade that, through the transcriptional coactivator YAP and its DNA-binding partners the Tead transcription factors, restrains organ growth in many tissues — acts in the pancreas, but deleting Hippo components paradoxically shrinks the pancreas despite increasing proliferation, because tissue architecture collapses. Mesenchyme-derived IGF2 is a major paracrine regulator of pancreatic growth. MicroRNAs and cell-cycle regulators (for example miR-302, which shortens S phase in early progenitors) modulate the progenitor pool size. Clonal fate mapping has shown that pancreas organogenesis proceeds through heterogeneous, transient multipotent progenitors rather than long-lived stem cells. Progenitor-number-limited size control has been demonstrated for additional organs: fetal nephron progenitor number limits kidney nephron endowment (the number of nephrons, the kidney's functional units, fixed before birth), respiratory progenitor number limits lung size, an epithelial progenitor pool limits thymus growth, and embryonic progenitor number limits adipose tissue expansion. Interspecies blastocyst complementation produced an additional twist: a rat-derived pancreas growing in a mouse host reaches mouse size, and a mouse-derived pancreas in a rat host reaches rat size, showing that host-scale extrinsic cues can override donor-intrinsic species programs. Yet, as reviews through 2021 emphasize, no mechanistic account explains how the pancreatic progenitor-number constraint is imposed, and no principle classifies organs by size-control mode.

Problem Statement

Determine the mechanism that makes final pancreas size a function of embryonic progenitor cell number, and establish how far this progenitor-number-limited mode of size control applies across organs. The problem has three linked parts, jointly serving one objective — a mechanistic explanation of progenitor-number-limited organ size determination. (1) Localization of size information: establish whether pancreatic progenitor proliferative output is capped cell-autonomously (for instance by an intrinsic division-counting program or a fixed proliferative set point per progenitor) or by non-epithelial components such as the pancreatic mesenchyme and its paracrine signals (for example mesenchyme-derived IGF2), or by host-level scaling cues — as suggested by interspecies chimeras in which donor-derived pancreata attain host-species size. (2) Molecular mechanism: determine whether and how the candidate signaling pathways and transcriptional programs — the FGF10–FGFR2b receptor axis, the Notch cell-contact signaling pathway, canonical Wnt/β-catenin signaling, the Hippo pathway and its YAP–Tead effector, and microRNA and cell-cycle regulators — or a different mechanism impose the limit on progenitor pool size and proliferative capacity, and demonstrate that perturbing the implicated mechanism reproducibly changes final pancreas size through the progenitor-number mechanism rather than through unrelated effects on differentiation or tissue architecture. (3) Generality: determine which organs follow progenitor-number-limited size control versus regulative, functional-demand-mediated compensation, and provide a principle that predicts an organ's mode — and its associated regenerative capacity — from measurable developmental or architectural features. Two facets of the original question are treated as resolved or subsumed: the lineage basis of organogenesis (transient multipotent progenitors, not long-lived stem cells, for the source organs) and the literal liver-complementation experiment (subsumed by the liver-regeneration literature showing liver mass adjusts to organismal demand).

References

  1. Stanger BZ, Tanaka AJ, Melton DA (2007). Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445(7130):886–891. doi:10.1038/nature05537, https://doi.org/10.1038/nature05537
  2. Stanger BZ (2008). Organ size determination and the limits of regulation. Cell Cycle 7(3):318–324. doi:10.4161/cc.7.3.5348, https://doi.org/10.4161/cc.7.3.5348
  3. Penzo-Méndez AI, Stanger BZ (2015). Organ-Size Regulation in Mammals. Cold Spring Harbor Perspectives in Biology 7(9):a019240. doi:10.1101/cshperspect.a019240, https://doi.org/10.1101/cshperspect.a019240
  4. Boulan L, Léopold P (2021). What determines organ size during development and regeneration? Development 148(1):dev196063. doi:10.1242/dev.196063, https://doi.org/10.1242/dev.196063
  5. Landsman L, Nijagal A, Whitchurch TJ, VanderLaan RL, Zimmer WE, Mackenzie TC, Hebrok M (2011). Pancreatic Mesenchyme Regulates Epithelial Organogenesis throughout Development. PLoS Biology 9(9):e1001143. doi:10.1371/journal.pbio.1001143, https://doi.org/10.1371/journal.pbio.1001143
  6. Hammerle CM, Sandovici I, Brierley GV, Smith NM, Zimmer WE, Zvetkova I, Prosser HM, Sekita Y, Lam BYH, Ma M, Cooper WN, Vidal-Puig A, Ozanne SE, Medina-Gómez G, Constância M (2020). Mesenchyme-derived IGF2 is a major paracrine regulator of pancreatic growth and function. PLoS Genetics 16(10):e1009069. doi:10.1371/journal.pgen.1009069, https://doi.org/10.1371/journal.pgen.1009069
  7. George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE (2012). Hippo Signaling Regulates Pancreas Development through Inactivation of Yap. Molecular and Cellular Biology 32(24):5116–5128. doi:10.1128/MCB.01034-12, https://doi.org/10.1128/MCB.01034-12
  8. Ahuja N, Maynard C, Bierschenck T, Cleaver O (2025). Characterization of Hippo signaling components in the early dorsal pancreatic bud. Gene Expression Patterns 55:119392. doi:10.1016/j.gep.2025.119392, https://doi.org/10.1016/j.gep.2025.119392
  9. Escot S, Willnow D, Naumann H, Di Francescantonio S, Spagnoli FM (2018). Robo signalling controls pancreatic progenitor identity by regulating Tead transcription factors. Nature Communications 9(1):5082. doi:10.1038/s41467-018-07474-6, https://doi.org/10.1038/s41467-018-07474-6
  10. Yang ZZ, Snider CG, Parchem RJ (2026). miR-302 regulates pancreatic progenitor pool and pancreatic size. Biology Open 15(1):bio062353. doi:10.1242/bio.062353, https://doi.org/10.1242/bio.062353
  11. Larsen HL, Martín-Coll L, Nielsen AV, Wright CVE, Trusina A, Kim YH, Grapin-Botton A (2017). Stochastic priming and spatial cues orchestrate heterogeneous clonal contribution to mouse pancreas organogenesis. Nature Communications 8(1):605. doi:10.1038/s41467-017-00258-4, https://doi.org/10.1038/s41467-017-00258-4
  12. Stolovich-Rain M, Fridlich O, Azulai S, Klochendler A, Anzi S, Magenheim J, Stein I, Mushasha F, Glaser B, Pikarsky E, Ben-Zvi D, Dor Y (2023). Extensive elimination of acinar cells during normal postnatal pancreas growth. Cell Reports 42(12):113457. doi:10.1016/j.celrep.2023.113457, https://doi.org/10.1016/j.celrep.2023.113457
  13. Nishimura W, Kapoor A, El Khattabi I, Jin W, Yasuda K, Bonner-Weir S, Sharma A (2015). Compensatory Response by Late Embryonic Tubular Epithelium to the Reduction in Pancreatic Progenitors. PLoS ONE 10(11):e0142286. doi:10.1371/journal.pone.0142286, https://doi.org/10.1371/journal.pone.0142286
  14. Kobayashi T, Yamaguchi T, Hamanaka S, Kato-Itoh M, Yamazaki Y, Ibata M, Sato H, Lee YS, Usui J, Knisely AS, Hirabayashi M, Nakauchi H (2010). Generation of Rat Pancreas in Mouse by Interspecific Blastocyst Injection of Pluripotent Stem Cells. Cell 142(5):787–799. doi:10.1016/j.cell.2010.07.039, https://doi.org/10.1016/j.cell.2010.07.039
  15. Yamaguchi T, Sato H, Kato-Itoh M, Goto T, Hara H, Sanbo M, Mizuno N, Kobayashi T, Yanagida A, Umino A, Ota Y, Hamanaka S, Masaki H, Rashid ST, Hirabayashi M, Nakauchi H (2017). Interspecies organogenesis generates autologous functional islets. Nature 542(7640):191–196. doi:10.1038/nature21070, https://doi.org/10.1038/nature21070
  16. Cebrián C, Asai N, D'Agati V, Costantini F (2014). The Number of Fetal Nephron Progenitor Cells Limits Ureteric Branching and Adult Nephron Endowment. Cell Reports 7(1):127–137. doi:10.1016/j.celrep.2014.02.033, https://doi.org/10.1016/j.celrep.2014.02.033
  17. Sui P, Li R, Zhang Y, Tan C, Garg A, Verheyden JM, Sun X (2019). E3 ubiquitin ligase MDM2 acts through p53 to control respiratory progenitor cell number and lung size. Development 146(24):dev179820. doi:10.1242/dev.179820, https://doi.org/10.1242/dev.179820
  18. Hedbacker K, Lu YH, Dallner O, Li Z, Fayzikhodjaeva G, Birsoy K, Han C, Yang C, Friedman JM (2020). Limitation of adipose tissue by the number of embryonic progenitor cells. eLife 9:e53074. doi:10.7554/eLife.53074, https://doi.org/10.7554/eLife.53074
  19. Jenkinson WE, Bacon A, White AJ, Anderson G, Jenkinson EJ (2008). An Epithelial Progenitor Pool Regulates Thymus Growth. The Journal of Immunology 181(9):6101–6108. doi:10.4049/jimmunol.181.9.6101, https://doi.org/10.4049/jimmunol.181.9.6101
  20. Zhang J, Wright KD, Mahoney Rogers AA, Barrett MM, Shim K (2014). Compensatory regulation of the size of the inner ear in response to excess induction of otic progenitors by fibroblast growth factor signaling. Developmental Dynamics 243(10):1317–1327. doi:10.1002/dvdy.24148, https://doi.org/10.1002/dvdy.24148
  21. Michalopoulos GK (2007). Liver regeneration. Journal of Cellular Physiology 213(2):286–300. doi:10.1002/jcp.21172, https://doi.org/10.1002/jcp.21172
  22. Villalba A, Gitton Y, Inoue M, Aiello V, Blain R, Toupin M, Mazaud-Guittot S, Rachdi L, Semb H, Chédotal A, Scharfmann R (2024). A 3D atlas of the human developing pancreas to explore progenitor proliferation and differentiation. Diabetologia 67(6):1066–1078. doi:10.1007/s00125-024-06143-2, https://doi.org/10.1007/s00125-024-06143-2